There are multiple chapters near you. Select your preferred chapter.
For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ ...
In the United States, SLE treatment trends between 2007 and 2023 show a continued reliance on glucocorticoids, despite advances in steroid-sparing agents.
Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.
Lupus can do irreversible harm to a person's organs, damaging the lungs, kidneys, heart, liver and other vital organs through ...
Lupus can do irreversible harm to a person’s organs, damaging the lungs, kidneys, heart, liver and other vital orga ...
Evaluation of primary aldosteronism testing in hypertensive patients with SLE in a tertiary hospital
S L E is a chronic multisystem autoimmune disease in which cardiovascular disease is a leading cause of mortality, with a ...
Recent decades have witnessed remarkable strides in the realm of clinical research and treatment for Systemic Lupus Erythematosus (SLE) and Sjögren’s ...
The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...
Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback